Reaction
Sicca Syndrome reporting signals
As of the last recalculation, Sicca Syndrome appears in 173 FAERS reports alongside 5 co-occurring drug terms. The strongest observed disproportionality signal is DURVALUMAB (PRR 97.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Durvalumab | 15 | 97.0 | 97.1 |
| Diclofenac Potassium | 6 | 69.2 | 69.2 |
| Rifaximin | 8 | 48.1 | 48.1 |
| Obinutuzumab | 6 | 45.4 | 45.4 |
| Lenvatinib | 9 | 34.8 | 34.8 |